

CLAIMS

What is claimed is:

1. A method of producing a mammalian glycosylated bikunin, the method comprising the steps of
 - a) obtaining mammalian cells which contain a nucleic acid coding sequence for the bikunin;
 - b) culturing the mammalian cells in a culture system under conditions sufficient to allow the cells to express the bikunin, said mammalian cells being capable of glycosylating the bikunin; and
 - c) recovering the glycosylated bikunin from the culture system.
2. An isolated mammalian glycosylated bikunin.
3. The glycosylated bikunin of claim 2, wherein the bikunin has a deduced amino acid sequence which is at least 80% identical over at least 40 residues to SEQ ID NO:1.
4. The glycosylated bikunin of claim 2, wherein the bikunin has a deduced amino acid sequence which is at least 90% identical over at least 50 residues to SEQ ID NO:1.
5. The glycosylated bikunin of claim 2, wherein the bikunin has a deduced amino acid sequence given by SEQ ID NO:1.
6. The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2, 3) linkage.

7. The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2, 6) linkage.

8. The glycosylated bikunin of claim 2 wherein the glycosylated bikunin comprises at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2, 3) linkage and at least one sialic acid residue bonded within the glycosylated bikunin via an alpha-(2, 6) linkage.

9. The glycosylated bikunin of claim 2 in a pharmaceutically acceptable carrier.

10. A mammalian cell line which has been engineered using recombinant DNA techniques to express a mammalian glycosylated bikunin.

11. The cell line of claim 10 wherein the cell line is a CHO cell line.

12. The cell line of claim 11 wherein the cell line is designated FD3-1 (ATCC accession number _____, deposited November 12, 1999).

13. The cell line of claim 10 wherein the cell line is an HKB cell line.

14. A method of producing a mammalian glycosylated monokunin, the method comprising the steps of

- d) obtaining mammalian cells which contain a nucleic acid coding sequence for the monokunin;
- e) culturing the mammalian cells in a culture system under conditions sufficient to allow the cells to express the monokunin, said mammalian cells being capable of glycosylating the monokunin; and
- f) recovering the glycosylated monokunin from the culture system.

15. An isolated mammalian glycosylated monokunin.

16. The glycosylated monokunin of claim 15, wherein the monokunin has a deduced amino acid sequence which is at least 80% identical over at least 40 residues to SEQ ID NO:1.
17. The glycosylated monokunin of claim 15, wherein the monokunin has a deduced amino acid sequence which is at least 90% identical over at least 50 residues to SEQ ID NO:1.
18. The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2, 3) linkage.
19. The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2, 6) linkage.
20. The glycosylated monokunin of claim 15 wherein the glycosylated monokunin comprises at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2, 3) linkage and at least one sialic acid residue bonded within the glycosylated monokunin via an alpha-(2, 6) linkage.
21. The glycosylated monokunin of claim 15 in a pharmaceutically acceptable carrier.
22. A mammalian cell line which has been engineered using recombinant DNA techniques to express a mammalian glycosylated monokunin.
23. The cell line of claim 22 wherein the cell line is a CHO cell line.
24. The cell line of claim 22 wherein the cell line is an HKB cell line.

add B5